A 2018 evaluate of sixteen scientific tests of cannabis-primarily based medicines for neuropathic agony, nearly all of which analyzed a cannabinoid planning called nabiximols (model title Sativex; a mouth spray containing both THC and CBD which is accredited in a few nations around the world but not